NovaBay Pharma (NBY) Announces $3M Convertible Note Financing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall St rises on cooler inflation data, big bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
NovaBay Pharmaceuticals Announces $3.0 Million Convertible Note Financing
April 27, 2023 4:47 PM EDTEMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (NovaBay or the Company) announced today that it has entered into a securities purchase agreement with institutional accredited investors (Purchasers) in connection with a private placement to issue secured senior convertible debentures (the Debentures) and two series of new warrants exercisable for NovaBay common stock (the Warrants). The private placement is expected to close upon the satisfaction of closing conditions in the securities purchase agreement, which is expected to occur on or about May 1, 2023 or as soon as practicable thereafter. NovaBay intends to use the net proceeds... More
